drugset
drugset / Trial / NCT07228078

Open-Label Extension Protocol to SNK01-AD01 Study

NCT07228078 ↗

Phase 2 Recruiting 30 enrolled NKGen Biotech, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Open-Label Extension Protocol to SNK01-AD01 Study

Timeline

Start
2025-06-30
Primary completion
2028-04
Completion
2028-04

Drugs

EvaluationDrugModalityDoseRoute
Subject TROCULEUCEL Cell therapy — Intravenous

Indications

Alzheimer disease